CTOs on the Move


 
NICO gives hope to patients with primary and secondary brain tumors, cysts and hemorrhagic strokes.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

NICO raised $12.5M on 11/19/2018

Similar Companies

Hospitals of Ontario Pension Plan

Established in 1960, the Healthcare of Ontario Pension Plan (HOOPP) is a multi-employer defined benefit pension plan for Ontario`s hospital and community-based healthcare sector. We serve more than 435,000 members who provide valued healthcare services at more than 630 employers across the province. At HOOPP, we exist to provide a stable and reliable pension for our members that starts in retirement and is paid for life. As one of Canada`s largest and most respected pension plans, HOOPP`s net assets reached $103.7 billion at the end of 2022 and our funded status remained strong at 117%. HOOPP`s core values - professional, accountable, collaborative, compassionate and trustworthy - guide our every interaction with our members, employers and employees. We`ve become one of Canada`s leading pension plans by consistently challenging ourselves and embracing innovation. From our unique investment management approach to our innovative technology and thought-provoking research, we constantly seek to push the boundaries, and we do this by hiring passionate, forward-thinking people. Our high-performance culture is founded on collaboration, respect and belonging. HOOPP is an equal opportunity employer and we`re proud of our diversity. We select applicants for employment solely on the basis of their qualifications. Should you require accommodation because of a disability during the recruitment and selection process, please contact our Human Resources team. We will be happy to consult with you so that arrangements can be made for reasonable accommodation.

Apeel Sciences

We use our natural plant-based technologies to protect crops and harvested produce, helping to eliminate food spoilage and reduce reliance on chemicals. Accomplishing our mission means we will waste less food, water and energy, helping to preserve our natural ecosystems while creating economic opportunities for the 500 million small family farms worldwide. In the future, less food will be wasted, we will use smarter, more natural methods for growing and protecting crops, and there will be an abundance of fresh food for everyone.

E-Scape Bio

E-Scape Bio is a preclinical stage biopharmaceutical company focused on the discovery and development of therapies to treat genetically defined, neurodegenerative diseases.

Regenacy Pharmaceuticals

Regenacy Pharmaceuticals is developing a novel, disease-modifying approach to treating peripheral neuropathies that goes beyond pain and symptom management to restore peripheral nerve function.

Life Biosciences

Life Biosciences was co-founded in 2017 by David Sinclair, PhD, a professor in the Department of Genetics at Harvard Medical School, and Tristan Edwards, who developed its innovative structure as Chapter Two in his life, after a highly successful career as a global institutional investor, working across all asset classes. The company`s novel Daughter company business model creates the robust research ecosystem required to forge industry leadership through two investment strategies. The first is to establish new companies, thereby extending the research of visionary scientists around the world. Secondly, Life Biosciences invests in other groundbreaking firms, providing them with the resources to maximize their potential. In addition to Lua, there are six Daughter companies working independently and together within the Life Biosciences research environment. The company provides Daughter companies with the resources required to maximize human potential, including Lua`s AI-driven data and communications platform, experienced management, drug development experience, and a 25,000 square foot, state-of-the-art vivarium, robotics and drug screening facility in Cambridge, Mass, augmented by laboratories and offices on four continents. Co-founded in 2017 by David Sinclair, PhD, AO, and Tristan Edwards, Life Biosciences is the first and largest biotech company addressing the eight pathways of age-related decline (ARD) in totality. It has established Daughter companies around the world, led by a Dream Team of respected scientists, to independently and collaboratively attack these pathways through pioneering research and product development. The company provides Daughter companies with resources to maximize human potential, including Lua`s AI-driven data and communications platform, drug development experience, and a 25,000 square foot, state-of-the-art vivarium, robotics and drug screening facility. Life Biosciences seeks to increase healthspans for everyone, including companion animals, by addressing the systemic breakdown of the body, rather than as a series of isolated symptoms and conditions.